San Diego and Cologne, Germany–ACEA Biosciences (ACEA), a pioneer and leader in label-free real-time cell analysis instrumentation, and Ncardia, a leading expert in human cardiovascular stem cell technology, disease modelling and cell-based assay products and services, announced today that they have established a global partnership to provide comprehensive solutions for cardiac drug discovery and cardiac safety assessment. This multifaceted partnership will include the joint development of applications, co-marketing, and commercial activities. Central to this partnership will be the coupling of ACEA’s innovative xCELLigence® Real-Time Cell Analysis (RTCA) Cardio and CardioECR instruments with Ncardia’s fully functional Pluricyte® and Cor.4U® human iPSC-derived cardiomyocytes, providing a complete assay system for pure and applied cardiomyocyte research.
Axiogenesis, a worldwide leading provider of induced pluripotent stem cell (iPS cell) products, has added a vital new service offering, Cardio.Force. This newest service offering includes assay services for iPSC-derived cardiomyocyte functionality and toxicity assessment.
Cardio.Force is based on the Axiogenesis 8 channel Cor.4CE assay device. Currently, 96well versions are in development to further increase the throughput and reduce cost per data point. [Read more…]